ArticleCell communication and signaling : CCS2025
Mechanistic insights into targeting APLN/APJ for ameliorating testosterone deficiency and reproductive disorders in diabetic mice.
Article in Cell communication and signaling : CCS, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Concomitant Effect of Hypothyroidism with Obesity on Testicular and Sperm Function in Male ICR Mice: Involvement of TGFβ/SMAD Signaling.Cell biochemistry and biophysics · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
Type 2 diabetes mellitus (T2DM) is frequently associated with testosterone deficiency, which affects male reproductive function. Currently, exogenous testosterone replacement therapy poses inherent risks, underscoring the need to develop safer and more effective treatment strategies. This study aimed to elucidate the mechanism by which ML221, a potent apelin receptor (APJ) functional antagonist, promotes testosterone secretion, and alleviates reproductive dysfunction. Diabetic mouse models demonstrated reduced testosterone levels, impaired spermatogenesis, and low sperm quality. Elevated APLN expression impaired Leydig cell function and testosterone synthesis. Treatment with ML221 restored testosterone levels and spermatogenesis in diabetic mice. Mechanistically, ML221 regulated Leydig cell metabolism by elevating S-D-lactoylglutathione levels, reducing mitochondrial reactive oxygen species, preserving mitochondrial membrane potential, and enhancing adenosine triphosphate production. At the epigenetic level, ML221 enhanced the binding of nuclear receptor subfamily 2 group F member 2 to the promoters of testosterone-synthesizing genes, thereby facilitating testosterone biosynthesis. These findings advance the understanding of the male reproductive system in the context of diabetes and highlight ML221 as a potential therapeutic approach for T2DM-induced testosterone deficiency.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.